UBS and Citi Go Bullish on Gilead Sciences (GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) is 1 of the most undervalued bluish spot stocks to bargain now.

On January 7, 2026, reports highlighted that analysts are progressively assured successful Gilead Sciences, Inc. (NASDAQ:GILD)’s short- and medium-term outlook, driven by optimism astir the company’s HIV franchise. On that day, UBS expert Michael Yee upgraded the banal from ‘Neutral’ to ‘Buy’ and raised the firm’s terms people from $112 to $145, according to The Fly. The expert expects beardown HIV pre-exposure prophylaxis income from Yeztugo, which could perchance boost some gross and earnings. At the aforesaid time, the expert expects visibility into the company’s outer-year maturation trajectory to improve. Furthermore, Yee highlighted the company’s absorption connected prevention-based HIV therapies, which reflects a strategical improvement of the company’s halfway antiviral concern toward much durable, growth-oriented request drivers.

This affirmative update was accompanied by different connected the aforesaid day, with Citi’s expert Geoff Meacham raising the firm’s people from $135 to $140 and maintaining a ‘Buy’ rating.

The bullish expert sentiment was reinforced earlier, connected December 22, 2025, erstwhile Gilead Sciences, Inc. (NASDAQ:GILD) exercised its enactment to exclusively licence Assembly Biosciences’ long-acting HSV helicase-primase inhibitor programs, ABI-1179 and ABI-5366. The deal, supported by affirmative Phase 1b information and once-weekly oral dosing potential, extends the company’s extremity of expanding its antiviral pipeline into areas with important unmet request and constricted competition. This determination supports the company’s semipermanent maturation optionality beyond HIV.

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, focuses connected the improvement and commercialization of innovative medicines crossed HIV, liver disease, oncology, hematology, and inflammatory conditions.

While we admit the imaginable of GILD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.

Disclosure: None.